Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?-Reference-Cited by-同舟云学术

Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?

Published:2016-11-28 Issue:5 Volume:24 Page:1406-1413
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Bednar Filip,Zenati Mazen S.,Steve Jennifer,Winters Sharon,Ocuin Lee M.,Bahary Nathan,Hogg Melissa E.,Zeh Herbert J.,Zureikat Amer H.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-016-5707-0.pdf

Reference30 articles.

1. Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015;33(16):1770–8. doi: 10.1200/JCO.2014.59.7930 .

2. Loehrer PJ, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105–12. doi: 10.1200/JCO.2011.34.8904 .

3. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2. Ann Oncol. 2008;19(9):1592–9. doi: 10.1093/annonc/mdn281 .

4. Hammel P, Huguet F, Van Laethem J-L, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. ASCO Meet Abstr. 2013;31(15_suppl):LBA4003. http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/LBA4003 . Accessed 28 Mar 2016.

5. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14(4):317–26. doi: 10.1016/S1470-2045(13)70021-4 .

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy;Anticancer Research;2023-08-30

2. Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival;Clinical Oncology;2023-05

3. Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress;World Journal of Gastrointestinal Surgery;2023-02-27

4. Irreversible Electroporation-Assisted Resection for Locally Advanced Pancreas Cancer;Surgical Innovation;2023-02-15

5. A 47-Year-Old Man with Advanced Distal Pancreatic Carcinoma and an Initial Partial Response to Chemotherapy Requiring Celiac Axis Reconstruction of the Common Hepatic Artery and Left Gastric Artery;American Journal of Case Reports;2022-08-11